KTRA
vs
S&P 500
KTRA
S&P 500
Over the past 12 months, KTRA has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
KTRA vs S&P 500
Performance Gap
KTRA vs S&P 500
Performance By Year
KTRA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kintara Therapeutics Inc
Glance View
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.
